"THLD's TH-302 for glioblastoma could be eligible for accelerated development."

— Philippa Gardner, Edison Investment Research (11/18/14)
more >

"THLD has initiated a large Phase 2 trial investigating TH-302."

— Philippa Gardner, Edison Investment Research (7/14/14)
more >

"Data from two of THLD's Phase 1/2 trials will be presented at ASCO."

— Philippa Gardner, Edison Investment Research (5/23/14)
more >